Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 5/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 2/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6233163 | 0.91 | PNP (0.58) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11661807 | 0.88 | PNP (0.62) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL380137 | 0.87 | PNP (0.50) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7217325 | 0.85 | PNP (0.49) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5431750 | 0.84 | GAA (0.48) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9845196 | 0.84 | ALDH1A1 (0.50) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7530556 | 0.84 | PNP (0.57) | PNPADORA2AKMT2AADORA2BADORA1 | |
| SCHEMBL28702160 | 0.84 | PNP (0.54) | PNPGAAKMT2AADORA2BGDA | |
| SCHEMBL27414457 | 0.84 | PNP (0.54) | PNPGAAKMT2AGDAALDH1A1 | |
| SCHEMBL4622185 | 0.84 | PNP (0.49) | PNPPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3217985-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | Universitat de València (ES) | 2017-09-20 | — | — | EP | claimed |
| WO-2016075285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | UNIVERSITAT DE VALÈNCIA (ES) | 2016-05-19 | — | — | WO | claimed |
| EP-1636230-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2004110379-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2004-12-23 | — | — | WO | claimed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| US-4980379-A | ENHANCING EFFICIENCY BY REDUCING ADENOSINE LEVELS | THE UNIVERSITY OF VIRGINIA (US) | 1990-12-25 | — | — | US | claimed |
| JP-9003094-A | — | — | None | — | — | JP | disclosed |
| JP-61088884-A | — | — | None | — | — | JP | disclosed |
| EP-4436567-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | Astrocyte Pharmaceuticals, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-110944994-B | Quinoxaline derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023091791-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-10391041-B2 | Sheet-shaped hair cosmetic and hair treatment method and scalp-wiping method using same | KAO CORPORATION (JP) | 2019-08-27 | — | — | US | disclosed |
| JP-H093094-A | SERRATIO PROTEASE INHIBITOR | MERCIAN CORP | 1997-01-07 | — | — | JP | disclosed |
| EP-0267607-B1 | 8-ARYLXANTHINES | MARION MERRELL DOW INC. (US) | 1991-11-27 | — | — | EP | disclosed |
| US-4980379-A | ENHANCING EFFICIENCY BY REDUCING ADENOSINE LEVELS | THE UNIVERSITY OF VIRGINIA (US) | 1990-12-25 | — | — | US | disclosed |
| US-4975432-A | IMPROVED BLOOD FLOW | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-12-04 | — | — | US | disclosed |
| EP-0267607-A1 | 8-Arylxanthines | MARION MERRELL DOW INC. (US) | 1988-05-18 | — | — | EP | disclosed |
| JP-S6188884-A | ENCEPHALINASE B-INHIBITING SUBSTANCE AND ITS PREPARATION | SANKYO CO LTD | 1986-05-07 | — | — | JP | disclosed |
| JP-S06188884-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | PNP 3194/4885PDE4A 818/4885PDE4B 1069/4885 |
| US-10391041-B2 | Sheet-shaped hair cosmetic and hair treatment method and scalp-wiping method using same | CUTA, SUCLG1, PRKDC | PNP 2781/4885PDE4A 2131/4885PDE4B 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.